These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 35778697)

  • 21. Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer.
    Yue Q; Zhang Y; Bai J; Duan X; Wang H
    Dis Markers; 2022; 2022():7765900. PubMed ID: 35774851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
    Yu ZL; Zhu ZM
    Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
    Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
    Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
    Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
    Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
    [No Abstract]   [Full Text] [Related]  

  • 25. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
    Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
    Front Oncol; 2021; 11():710767. PubMed ID: 34458149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A N6-methyladenosine-related long noncoding RNAs model for predicting prognosis in oral squamous cell carcinoma: Association with immune cell infiltration and tumor metastasis.
    Yang Q; Cheng C; Zhu R; Guo F; Lai R; Liu X; Li M
    Oral Oncol; 2022 Apr; 127():105771. PubMed ID: 35189585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer.
    Wu J; Cai Y; Zhao G; Li M
    J Clin Lab Anal; 2021 Jun; 35(6):e23779. PubMed ID: 33934391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
    Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
    BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
    Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
    J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
    Huang X; Wang HF; Huang S
    Front Genet; 2022; 13():906880. PubMed ID: 36061188
    [No Abstract]   [Full Text] [Related]  

  • 31. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
    Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
    Front Immunol; 2021; 12():806189. PubMed ID: 35095893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of m6A-Related lncRNAs Associated With Prognoses and Immune Responses in Acute Myeloid Leukemia.
    Li D; Liang J; Cheng C; Guo W; Li S; Song W; Song Z; Bai Y; Zhang Y; Wu X; Zhang W
    Front Cell Dev Biol; 2021; 9():770451. PubMed ID: 34869365
    [No Abstract]   [Full Text] [Related]  

  • 33. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
    Wu ZY; Shi ZY
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new risk model based on a 11-m
    Lei L; Li N; Yuan P; Liu D
    BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
    Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
    BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs.
    Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T
    Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885
    [No Abstract]   [Full Text] [Related]  

  • 37. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 38. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification.
    Gao C; Kong N; Zhang F; Tang T; Li J; Ding H; Sun Z; Wu L; Xu M
    BMC Med Genomics; 2022 Jan; 15(1):15. PubMed ID: 35093068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. m6A- and m5C- modified lncRNAs orchestrate the prognosis in cutaneous melanoma and m6A- modified LINC00893 regulates cutaneous melanoma cell metastasis.
    Shi HZ; Tian CC; Wu MY; Ma L; Sun JF; Chen H
    Skin Res Technol; 2024 Jul; 30(7):e13842. PubMed ID: 38965799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.